A diversified pharmaceutical platform combining API intermediates, CDMO, drug products, outsourced research and manufacturing, and proprietary product lines.
Mainland ChinaFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
473 matching companiesShowing 241–264 / 473
Allucent describes clinical pharmacology strategy, PK/PD, pharmacometrics, modeling, and simulation. Nuventra is part of Allucent and is not counted here as a separate independent provider.
Altasciences offers LC-MS/MS, ligand-binding assays, immunogenicity and biomarkers. Services should be matched to the intended study and assay requirements.
Canada / United StatesFull profile →
ChemPartner Pharmatech provides discovery, CMC, preclinical, and related research services through operating entities including Shanghai ChemPartner.
Mainland ChinaFull profile →
ICON lists population PK, PK/PD, exposure-response modeling, trial simulation, first-in-human dose prediction, and formulation-related IVIVC. These are service disclosures, not independent evidence of success for an individual project.
Aanastra discloses PEP-CAR, an anti-CD19 in vivo CAR-T strategy combining engineered RNA and targeting peptides for cancer and autoimmune disease. The public website does not establish a registered clinical program or validated patient outcomes.
Provides ADC and other bioconjugate discovery, process development, and GMP manufacturing, including antibody intermediates and payload-linker capabilities.
Mainland ChinaFull profile →
Combines products and services across tool compounds, biochemical reagents, molecular building blocks, and API/intermediate/drug-product research and manufacturing.
Mainland ChinaFull profile →
Extends molecular building-block products into medicinal chemistry, process development, and GMP API/drug-product manufacturing, including continuous-flow technology.
Mainland ChinaFull profile →
Provides one-stop drug development, regulatory submissions, and CMC/process services, based on clinical and preclinical research capabilities.
Mainland ChinaFull profile →
Pharmaceutical research subsidiaries provide discovery, CMC, clinical trials, BE/PK bioanalysis, SMO, and marketing authorization holder-related services.
Mainland ChinaFull profile →
Provides outsourced drug development, clinical, and CMC services, with CDMO and technology commercialization through subsidiaries including Saimer Pharmaceuticals.
Mainland ChinaFull profile →
AAVivo lists CD19 AVO-100, BCMA AVO-101, and dual BCMA/CD19 AVO-102 using T-cell-targeted AAV. The disclosed activities include vector production and construct optimization, not verified clinical dosing. AVO-103 is a TCR program and is kept separate from CAR-T.
United StatesFull profile →
AERA-109 is a targeted-LNP in vivo CAR-T candidate for B-cell-mediated autoimmune diseases, supported by mouse and nonhuman-primate studies. The pipeline projects clinical entry in the second half of 2026; a projected date is not proof that dosing has begun.
United StatesFull profile →
Focuses on clinical trial site management (SMO), providing coordination and project execution for sponsors and clinical sites.
Mainland ChinaFull profile →
Provides CMC, clinical operations, SMO, biosample analysis, data management/statistics, technology commercialization, and collaborative development.
Mainland ChinaFull profile →
Operates in medicinal and synthetic chemistry, DMPK, process development, and commercial manufacturing, alongside proprietary generic drug research, production, and sales.
Mainland ChinaFull profile →
Alaya is a preclinical in vivo CAR-T developer. Its disclosed polymeric nanoparticle platform encapsulates lentiviral CAR vectors for targeted T-cell transduction; this is a hybrid polymer/viral approach, not simply a nonviral polymer delivery system.
Combines gene-edited animal-model products and preclinical services with RenMice antibody discovery, licensing/transfers, and collaborative development.
Mainland ChinaFull profile →
The annual report discloses peptide drug CDMO, generic peptide APIs, and drug products; group financials include proprietary products.
Mainland ChinaFull profile →
The annual report discloses peptide APIs, self-selected products, and small-molecule CDMO services; this is not a pure-play service company.
Mainland ChinaFull profile →
The annual report’s key audit matters identify CDMO service revenue of RMB 1.03299 billion; the group also includes heparin APIs and drug products. A/H shares represent one group and are counted once.
Mainland ChinaFull profile →
The annual report separately discloses RMB 391.9 million in CDMO API/intermediate revenue, alongside generic APIs and drug products.
Mainland ChinaFull profile →
The annual report confirms CRO services through a virus-assessment platform, including clinical strain testing and antiviral drug/vaccine evaluation for pharmaceutical clients. Drugs and APIs remain the group’s core business; included as diversified.
Mainland ChinaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.